Cullinan Therapeutics annual return on equity
2021
2022
2023
2024
2025
Cullinan Therapeutics Return on Equity (ROE) Growth & History (CGEM)
Cullinan Therapeutics's return on equity was −44.02% for fiscal 2025.
View full Cullinan Therapeutics company overviewCullinan Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −44.02% | −11.95 pp |
| 2024 | 2024-12-31 | −32.06% | −1.08 pp |
| 2023 | 2023-12-31 | −30.98% | −54.15 pp |
| 2022 | 2022-12-31 | 23.17% | +44.19 pp |
| 2021 | 2021-12-31 | −21.02% | — |
Cullinan Therapeutics quarterly return on equity
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −15.61% | −2.19 pp |
| Q1 2026 | 2026-03-31 | −12.82% | −4.32 pp |
| Q4 2025 | 2025-12-31 | −11.79% | −3.97 pp |
| Q3 2025 | 2025-09-30 | −10.73% | −4.41 pp |
| Q2 2025 | 2025-06-30 | −13.42% | −5.65 pp |
| Q1 2025 | 2025-03-31 | −8.49% | −0.04 pp |
| Q4 2024 | 2024-12-31 | −7.82% | −2.66 pp |
| Q3 2024 | 2024-09-30 | −6.32% | +1.78 pp |
| Q2 2024 | 2024-06-30 | −7.77% | −1.23 pp |
| Q1 2024 | 2024-03-31 | −8.45% | +2.91 pp |
| Q4 2023 | 2023-12-31 | −5.16% | −0.38 pp |
| Q3 2023 | 2023-09-30 | −8.09% | −3.93 pp |
| Q2 2023 | 2023-06-30 | −6.54% | −40.72 pp |
| Q1 2023 | 2023-03-31 | −11.36% | −8.49 pp |
| Q4 2022 | 2022-12-31 | −4.78% | +2.71 pp |
| Q3 2022 | 2022-09-30 | −4.17% | −0.31 pp |
| Q2 2022 | 2022-06-30 | 34.19% | +37.58 pp |
| Q1 2022 | 2022-03-31 | −2.87% | −2.85 pp |
| Q4 2021 | 2021-12-31 | −7.49% | — |
| Q3 2021 | 2021-09-30 | −3.86% | — |
| Q2 2021 | 2021-06-30 | −3.39% | — |
| Q1 2021 | 2021-03-31 | −0.02% | — |
Cullinan Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Cullinan Therapeutics's return on equity decreased from −21.02% to −44.02%, a change of −23.00 percentage points. The latest reported quarter, Q2 2026, shows −15.61%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cullinan Therapeutics source filings ↗